Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2025-12-26 @ 1:06 AM
Study NCT ID:
NCT00825734
Status:
COMPLETED
Last Update Posted:
2014-12-22
First Post:
2009-01-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Sponsor:
SCRI Development Innovations, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03
Start Date Type:
None
Primary Completion Date:
2013-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-08
Completion Date Type:
ACTUAL
First Submit Date:
2009-01-19
First Submit QC Date:
None
Study First Post Date:
2009-01-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-11-21
Results First Submit QC Date:
None
Results First Post Date:
2014-12-22
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-12-16
Last Update Post Date:
2014-12-22
Last Update Post Date Type:
ESTIMATED